TAUOPATHIES TREATMENT MARKET ANALYSIS

Regional Analysis

Global Tauopathies Treatment Market - Regional Analysis

Among region, North America is estimated to hold a dominant position in the global tauopathies treatment market over the forecast period, owing to increasing launches of products. For instance, on May 3, 2023, Eli Lilly and Company, a U.S.-based pharmaceutical company announced positive results of the TRAILBLAZER-ALZ 2 Phase 3 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer\'s disease. The primary endpoint was of change from baseline until 18 months on the integrated Alzheimer\'s Disease Rating Scale (iADRS) while secondary endpoints of cognitive and functional decline were also met and showed highly statistically significant clinical benefits with similar magnitude. In this study, the primary endpoint (iADRS) showed 35% slowing of decline, and an important key secondary endpoint (Clinical Dementia Rating-Sum of Boxes, or CDR-SB) showed 36% slowing of decline (p<0.0001) over 18 months.

Geographies covered:

North America: U.S. and Canada

Latin America: Brazil, Argentina, Mexico, and Rest of Latin America

Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe

Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific

Middle East: GCC, Israel, and Rest of Middle East

Africa: South Africa, North Africa, and Central Africa